Clovis Oncology, Inc.
(NASDAQ : CLVS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.26%178.600.7%$1354.05m
MRKMerck & Co., Inc. 1.88%94.390.7%$1234.84m
PFEPfizer Inc. 1.90%52.620.9%$1115.96m
LLYEli Lilly & Co. 1.33%331.541.1%$1039.83m
BMYBristol-Myers Squibb Co. 0.94%76.671.0%$1000.78m
ABBVAbbVie, Inc. 0.39%154.531.9%$963.97m
AZNAstraZeneca Plc 1.20%66.301.0%$476.64m
SGENSeagen Inc. 0.10%176.955.7%$326.40m
GSKGSK Plc 0.21%43.390.2%$272.96m
TPTXTurning Point Therapeutics, Inc. -0.11%75.070.0%$199.07m
HZNPHorizon Therapeutics Plc -0.01%82.765.4%$174.09m
NVSNovartis AG -0.56%83.810.2%$171.31m
MRTXMirati Therapeutics, Inc. 1.56%73.091.6%$153.18m
ALNYAlnylam Pharmaceuticals, Inc. 0.45%151.408.1%$150.98m
NVONovo Nordisk A/S -0.92%110.220.1%$147.01m

Company Profile

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.